Latest news
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 12:42:53 GMTOEC Q1 2026 Earnings: Significant EPS Miss Highlights Operational Pressure - Analyst Consensus Shift - dars.gov.etdars.gov.et · Fri, 31 Jul 2026 17:41:16 GMTATNI Q1 2026 Earnings: Significant EPS Miss Highlights Operational Challenges - Revenue Growth Report - dars.gov.etdars.gov.et · Thu, 30 Jul 2026 19:34:32 GMTLITS Q4 2024 Earnings: Significant Earnings Miss Highlights Operational Challenges - Financial Summary - dars.gov.etdars.gov.et · Thu, 30 Jul 2026 08:33:24 GMTSCCE Q1 2026 Earnings: Significant EPS Miss Highlights Operational Challenges - Special Dividend Alert - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 07:00:00 GMT